The role of polar interactions in the molecular recognition of CD40L with its receptor CD40

Protein Science

Volumn 7, Issue 5, 1998, Pages 1124-1135

  Singh, Juswinder ^a   Garber, Ellen ^a   Van Vlijmen, Herman ^a   Karpusas, Michael ^a   Hsu, Yen Ming ^a   Zheng, Zhongli ^a   Naismith, James H ^b   Thomas, David ^a  

^a BIOGEN   (United States)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

CD40; CD40L; Homology modeling; Mutagenesis; TNF superfamily; X ray crystallography

Indexed keywords

ALANINE; CD40 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; METHIONINE; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL STRAIN COS1; CONTROLLED STUDY; HYDROPHOBICITY; LYMPHOCYTE PROLIFERATION; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

ANIMALIA;

EID: 0031836472     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560070506     Document Type: Article

References (44)

1. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, Fanslow WC, Belmont J, Spriggs MK. 1993. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259:990-993.
2. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, Clark EA, Smith CA, Grabstein KH, Cosman D, Spriggs MK. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357:80-82.
3. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, Roberts RL, Noelle RJ, Ledbetter JA, Francke U, Ochs HD. 1993. The CD40 ligand, gp39, is defective in activated T-cells from patients with X-linked Hyper-IgM syndrome. Cell 72:291-300.
4. Bajorath J, Aruffo A. 1997. Construction and analysis of a detailed 3D model of the ligand binding domain of the human B cell receptor CD40. Proteins Struct Funct Genet 27:59-70.
5. Bajorath J, Chalupny NJ, Marken JS, Siadak AW, Skonier J, Gordon M, Hollenbaugh D, Noelle RJ, Ochs HD, Aruffo A. 1995a. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry 34:1833-1844.
6. Bajorath J, Marken JS, Chalupny NJ, Spoon TL, Siadak AW, Gordon M, Noelle RJ, Hollenbaugh D, Aruffo A. 1995b. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry 34:9884-9892.
7. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W. 1993. Crystal structure of the soluble human 55kd TNF receptor-human TNF-b complex: Implications for TNF receptor activation. Cell 75:431-445.
8. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. 1983. CHARMM: A program for macromolecular energy minimization and dynamics calculations. J Comp Chem 4:187-217.
9. Bruccoleri RE, Novotny J. 1992. Antibody modeling using the conformational search program CONGEN. Immunomethods 1:96-106.
10. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, De Saint Basile G. 1993. CD40 ligand mutations in X-linked immunodeficiency with hyper IgM. Nature 567:541-543.
11. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. 1993. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328-1330.
12. Eck MJ, Sprang SR. 1989. The structure of TNF-a at 26A resolution. J Biol Chem 264:17595-17605.
13. Eck MJ, Ultsch M, Rinderknecht E, de Vos AM, Sprang SR. 1992. Lymphotoxin-b, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. J Biol Chem 267:2119-2122.
14. Farrah T, Smith CA. 1992. Emerging cytokine family. Nature 558:26.
15. Graf D, Korthauer U, Mages HW, Senger G. Kroczek RA. 1992. Cloning of TRAP, a ligand for CD40 on human T-cells. Eur J Immunol 22:3191-3194.
16. Grewal IS, Flavell RA. 1996a. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 17:410-414.
17. Grewal IS, Flavell RA. 1996b. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153:85-106.
18. Gruss, HJ, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Barcos M, Strockbine L, Armitage RJ, Dower SK. 1994. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkins disease. Blood 84:2305-2314.
19. Hendsch ZS, Tidor B. 1994. Do salt bridges stabilize proteins? A continuum electrostatic analysis. Protein Sci 5:211-226.
20. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D. 1997. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem 272:911-915.
21. Karpusas M, Hsu Y, Wang J, Thompson J, Lederman S, Chess L, Thomas D. 1995. The crystal structure of a TNF-like extracellular fragment of human CD40 ligand at 20 Å resolution. Structure 5:1031-1039.
22. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcom S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA. 1993. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyperIgM. Nature 561:539-541.
23. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 94:8789-8794.
24. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 557:434-438.
25. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. 1996. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.
26. + T cells that induces contact-dependent B cell differentiation help. J Exp Med 175:1091-1101.
27. Macchi P, Villa A, Strina D, Sacco MG, Morali F, Brugnoni D, Giliani S, Mantuano E, Fasth A, Anderson B, Zegers BJM, Cavagni G, Reznick I, Levy J, Zan-Bar I, Porat Y, Airo P, Plebani A, Vezzoni P, Notarangelo LD. 1995. Characterization of nine novel mutations in the CD40 ligand gene in patients with X-linked hyper IgM syndrome of various ancestry. Am J Hum Genet 56:898-906.
28. MacKerell AD Jr, Bashford D, Bellot M, Dunbrack R Jr, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Wiorkiewicz-Kuczera M, Karplus M. 1998. All-hydrogen empirical potential for molecular modeling and dynamics studies of proteins using CHARMM22 force field. J Am Chem Soc. In press.
29. Mohan C, Shi Y, Laman JD, Datta SK. 1995. Interaction between CD40 and its ligand gp39 in the development of murine nephritis. J Immunol 154:1470-1480.
30. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. 1995. Crystallographic evidence for dimerization of unliganded tumor necrosis factor. J Biol Chem 270:13303-13307.
31. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. 1996. Structures of the extracellular domains of the type I tumour necrosis factor receptor. Structure 4:1251-01262.
32. Naismith JH, Sprang SR. 1996. Tumor necrosis factor receptor superfamily. J Inflamm 47:1-7.
33. Naismith JH, Sprang SR. 1998. Moving to a modular system: The TNF receptor superfamily. Trends Biosci 23:74-78.
34. Nicholls A, Honig B. 1991. A rapid finite difference algorithm, utilizing successive over relaxation to solve the Poisson-Boltzman equation. J Comp Chem 12:435-445.
35. Nicholls A, Sharp KA, Honig B. 1991. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins Struct Funct Genet 11:281-296.
36. Peitsch MC, Jongeneel CV. 1993. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol 5:233-238.
37. Ramesh N, Fuleihan R, Ramesh V, Lederman S, Yellin MJ, Sharma S, Chess L, Rosen FS, Geha RS. 1993. Novel deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int Immunol 5:769-774.
38. Renshaw BR, Fanslow WC, Armitage RJ, Cambell KA, Liggit D, Wright B, Davison BL, Maliszewski CR. 1994. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 180:1889-1900.
39. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R. 1995. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 25:596-603.
40. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato T, Maliszewski CR, Fanslow WC. 1992. Recombinant human CD40 ligand stimulates B-cell proliferation and immunoglobulin E secretion. J Exp Med 176:1543-1550.
41. Stamenkovic I, Clark EA, Seed B. 1989. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 8:1403-1410.
42. Xu D, Lin SL, Nussinov R. 1997. Protein binding versus protein folding: The role of hydrophilic bridges in protein associations. J Mol Biol 265: 68-84.
43. Xu J, Foy TM, Laman JD, Elliot EA, Dunn JJ, Waldschmidt TJ, Eisemore J, Noelle RJ, Flavell RA. 1994. Mice deficient for the CD40 ligand. Immunity 7:423-431.
44. Yellin MJ, Sippel K, Inghirami G, Covey LR, Lee JJ, Sinning J, Clark EA, Chess L, Lederman S. 1994. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol 152:598-608.